CLDI (Calidi Biotherapeutics) Cash, Cash Equivalents, Marketable Securities : $10.56 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Cash, Cash Equivalents, Marketable Securities?

Calidi Biotherapeutics's quarterly cash, cash equivalents, marketable securities increased from Sep. 2024 ($1.90 Mil) to Dec. 2024 ($9.59 Mil) and increased from Dec. 2024 ($9.59 Mil) to Mar. 2025 ($10.56 Mil).

Calidi Biotherapeutics's annual cash, cash equivalents, marketable securities increased from Dec. 2022 ($0.37 Mil) to Dec. 2023 ($1.95 Mil) and increased from Dec. 2023 ($1.95 Mil) to Dec. 2024 ($9.59 Mil).

Calidi Biotherapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Calidi Biotherapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics Cash, Cash Equivalents, Marketable Securities Chart

Calidi Biotherapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash, Cash Equivalents, Marketable Securities

0.42

2.14

0.37

1.95

9.59

Calidi Biotherapeutics Quarterly Data
	Dec20	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial								1.14	0.84	1.90	9.59	10.56

Calidi Biotherapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Calidi Biotherapeutics (AMEX:CLDI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Calidi Biotherapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.calidibio.com

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.